Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 40Pancreatic Neoplasms 17Breast Neoplasms 17Esophageal Neoplasms 14Neoplasms 13Stomach Neoplasms 12Lung Neoplasms 12Triple Negative Breast Neoplasms 11Rectal Neoplasms 11Neoplasm Metastasis 11Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Colorectal Neoplasms 10Small Cell Lung Carcinoma 9Ovarian Neoplasms 9Head and Neck Neoplasms 7Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Nasopharyngeal Carcinoma 5Leukemia, Myeloid, Acute 5Endometrial Neoplasms 5Recurrence 4NSCLC 4Mouth Neoplasms 4Colonic Neoplasms 4Lymphoma 3Glioma 3Cholangiocarcinoma 3Adenocarcinoma Of Esophagus 3Urinary Bladder Neoplasms 2

Interventions

Trastuzumab 9pyrotinib 6pertuzumab 4Paclitaxel 3Docetaxel 3Capecitabine 3tucatinib 2Neoadjuvant Therapy 2trastuzumab deruxtecan 1neratinib 1inavolisib 1Taxoids 1Protons 1Isovaleryl-CoA Dehydrogenase 1Injections 1Genetic Testing 1Drug Therapy 1Cyclophosphamide 1Carboplatin 1Blood Specimen Collection 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × HER2-positive Breast Cancer × Drug Therapy × Clear all
NCT04481932 2020-07-22

Trastuzumab Combined With Pyrrolidine and Chemotherapy for Locally HER2 Positive Breast Cancer

Peking University

Phase 2 Recruiting
104 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡